C eliac disease is a lifelong disorder caused by ingested cereal-derived gluten in predisposed individuals. 1 Screening studies have shown the prevalence in the European and North American population to be 1%-2%, and to be increasing over time. [2] [3] [4] [5] Serum transglutaminase 2 (TG2ab) and endomysial antibodies (EmA) are used widely in first-line case-finding for further endoscopic studies, but demonstration of small-bowel mucosal damage still is required for the diagnosis in adults. 1, 6 Since celiac disease is common but difficult to detect because of the heterogeneous clinical picture, a widescale screening of the whole population with noninvasive serologic tests frequently has been suggested. 7, 8 However, the only current treatment of the condition, a lifelong strict glutenfree diet (GFD), is restrictive and difficult to maintain and thus the positive effects of the screening are not straightforward. 9 There have been some previous studies exploring the benefits of a GFD in screening-detected celiac disease patients, but the results have been somewhat inconsistent, in particular with asymptomatic subjects [10] [11] [12] [13] [14] ; hitherto randomized studies have been lacking. A further problem is that wide-scale screening frequently detects seropositive subjects who are apparently asymptomatic and evince only mild enteropathy or even normal small-bowel mucosa; it has been unclear whether all such individuals in fact suffer from a true gluten-induced clinical disease. 15 The aim of this randomized trial was to establish whether asymptomatic adults with positive EmA benefit from a serologic screening and subsequent GFD. Because celiac disease is known to run in families, recruitment was executed by screening at-risk relatives of celiac patients. By reason of its high specificity, EmA was selected as the inclusion criterion. 1 contacting patient support groups. Altogether, 3031 individuals volunteered for evaluation of serum celiac antibodies (Supplementary Figure 1) . Exclusion criteria were a previous diagnosis of celiac disease, age younger than 18 years, evident clinical symptoms, dietary gluten restriction, severe contemporary illness or immunosuppressive medication, ongoing or planned pregnancy, and study refusal. EmA-positive adults (age, 18-75 y) who considered themselves asymptomatic and had no exclusion criteria were invited to participate in a further prospective study. The symptoms were interviewed systemically with similar questions each time by a study physician and asymptomatic patients were defined as those with an absence of abdominal pain (>3 pain episodes over at least 3 months interfering with function), constipation (<3 bowel movements per week or difficulty during defecation), and diarrhea (!3 loose stools/day). The subjects also were asked if they suffered from any known extraintestinal symptom of celiac disease, such as joint pain, blistering rash, or unexplained neurologic symptoms. Furthermore, the presence of alarm symptoms, including unexplained severe weight loss, vomiting, frequent or continuous fever, or rectal bleeding, was questioned. Celiac disease was defined as the presence of positive EmA and gluten-dependent enteropathy. 15 
Study Protocol
Of the 3031 screened subjects, 148 were EmA positive. Of these, 108 were not eligible (67 females, 41 males) and were excluded (Supplementary Figure 1) . Reasons for exclusion were as follows: age younger than 18 (20 girls, 9 boys) or older than 75 years (6 women, 1 man), clinical symptoms (27 women, 19 men), contemporary illness (5 women, 3 men), pregnancy (n ¼ 2), and study refusal (7 women, 9 men). Altogether 40 eligible subjects were randomized to either a GFD group or a normal gluten-containing diet (gluten) group (Supplementary Figure 1) . Randomization was performed by means of random number tables with permuted blocks; the study nurse responsible was masked to patient characteristics. A gastrointestinal endoscopy with small-bowel mucosal biopsy specimens was performed, the biopsy specimens, however, were blinded from the study researchers and not read until the trial was completed after 2 years. Analysis was performed of serologic and laboratory parameters, clinical symptoms, quality-of-life scores, bone mineral density (BMD), body mass index (BMI), and body composition. All investigations were repeated after 1 year. Thereafter, an option to start a GFD was offered in the gluten group, whereas subjects in the GFD group were allowed to resume gluten consumption, and a third study visit was scheduled after another year (Supplementary Figure 1) . To ensure a strict GFD, a dietitian counseled all participants at baseline and after 1 year on diet. The randomized subjects were encouraged not to take any vitamin supplements during the trial.
The study was approved by the Ethics Committee of Tampere University Hospital and each subject provided written informed consent. The participants could contact the responsible physicians at any time or withdraw from the study without a specific reason. If there was suspicion of significant gluten-induced symptoms or severe complications the subject was withdrawn from the study and referred for further investigations. Without the present screening study these subjects would have remained unrecognized and continued on a gluten-containing diet.
All authors had access to the study data, and reviewed and approved the final manuscript. This study has been registered at clinicaltrials.gov; identification number NCT01116505.
Measurements
Serology and genetics. IgA class EmA were determined by an indirect immunofluorescence method using human umbilical cord as substrate. 16 A serum dilution of 1:!5 was considered positive 15, 16 and further diluted to 1:50-1:4000. IgA-class TG2ab (Celikey; Phadia, Freiburg, Germany) and antibodies against IgA/IgG class deamidated gliadin peptides (DGPab) (Inova Diagnostics, San Diego, CA) were investigated by an enzyme-linked immunosorbent assay. For TG2ab values, 3.0 U or greater was considered positive in line with recent studies 17, 18 ; for DGPab values, 20 U or greater was considered positive as recommended by the manufacturer. In serology we have standardized the tests on a European level and we are 1 of the 6 reference laboratories for the international quality control network (UK National External Quality Assessment) for celiac antibody tests. Accredited hospital laboratories use our service laboratory for endomysial antibody testing. Periodic testing is performed in our laboratory to maintain certification. Genotyping for celiac disease-associated HLA-DQB1*02 and DQB1*0302 alleles was performed with the SSPTM DQB1 low-resolution kit (Olerup SSP AB, Saltsjöbaden, Sweden).
Gastrointestinal symptoms and health-related quality of life. Possible unrecognized symptoms were evaluated by the Gastrointestinal Symptoms Rating Scale (GSRS), which covers 5 symptom subdimensions: diarrhea, indigestion, constipation, abdominal pain, and reflux. 19 Ratings are based on a 7-grade Likert scale, ranging from no symptoms (grade 1) to severe symptoms (grade 7). Values in each subdimension are calculated as a mean of the relevant items and the GSRS total score is calculated as a mean of all items. The Psychological General Well-Being (PGWB) and the Short-Form 36 (SF-36) were used to assess health-related quality of life. 20, 21 The PGWB comprises 6 subdimensions: anxiety, depression, wellbeing, self-control, general health, and vitality. The scoring is based on a 6-grade Likert scale in which higher scores indicate better quality of life. The SF-36 comprises 8 subdimensions: physical functioning, role limitations owing to physical problems, bodily pain, general health, vitality, social functioning, role limitations owing to emotional problems, and mental health. The scores range from 0 to 100, with higher scores indicating better health and quality of life. Patients' subjective perception of their health was evaluated by a visual analogue scale (VAS). The VAS ranged from 0 to 100 mm, with higher values indicating better health. X-ray absorptiometry (Lunar Prodigy Advance, GE Healthcare, Waukesha, WI). BMD values were expressed as T-scores and as age-and sex-matched Z-scores. Changes in BMD were calculated as g/cm 2 . BMI was determined as weight (kg)/height (m) 2 ; a value less than 18.5 was considered underweight, 18.5-24.9 was considered normal, 25.0-29.9 was considered overweight, and 30.0 or higher was considered obese.
Small-bowel mucosal morphology and inflammation. At each visit (at baseline, after 1 year, and after 2 years), an upper gastrointestinal endoscopy with 6 biopsy specimens taken from the duodenum was performed and the samples were coded and stored. Upon completion of the study (after the 2-year visit) the biopsy results were read and villous height crypt/depth ratio (Vh/CrD) was measured, and the density of CD3þ and gdþ intraepithelial lymphocytes (IEL) were counted as previously described. 22 Reference values were as follows: Vh/CrD greater than 2.0, CD3þ IEL less than 37 cells/mm, and gdþ IEL less than 4.3 cells/mm. 22 Other evaluations. At each study visit, the subjects' health and medications were registered. After 1 year on a GFD they were asked about their dietary adherence, difficulties in maintaining the diet, and willingness to continue the diet in the future. Thereafter, they also were asked what they now thought about their celiac disease screening.
Statistical Analyses
The primary outcome of the study defined a priori was a change in the Vh/CrD. Previous results have shown a standard deviation of 0.5 for Vh/CrD and a similar change in this value has been considered clinically relevant. 15, 23 Consequently, to provide 80% statistical power at a significance level of 0.05, 17 patients would be needed. Based on an estimated attrition rate of 15%, we enrolled 20 subjects in each group. The chi-square test in cross-tabulations and a 2-sided Student t test or the Mann-Whitney U test were used to compare differences between the groups, and a paired t test or the Wilcoxon signedrank test as used to compare changes within a group. A P value less than .05 was considered significant. If a subject failed to answer 1 item in the questionnaire the missing answer was replaced by the median value of the other scores. If 2 or more items were missing the questionnaire was rejected. Analyses were conducted on an intention-to-treat principle. Corrections for multiple comparisons were not made here because we had one predefined primary outcome and the rest were secondary outcomes; in addition, no subgroup analyses were performed. 24 All analyses were conducted in cooperation with an experienced statistician.
Results
The randomized study groups were comparable with respect to age, sex, medical history, and associated conditions (Table 1) . One subject in the gluten group started a GFD after randomization and 2 patients refused the 2-year endoscopy. None of the patients in the GFD group was willing to restart gluten, and none was withdrawn as a result of major symptoms or complications. Because subjects in the GFD group already had adhered to the diet for 1 year at the time of the second endoscopy, it was considered unnecessary or even unethical to perform a biopsy for a third time after 2 years on the diet.
HLA Typing and Serology
All subjects had the celiac disease-associated HLA DQ2 or DQ8. The median EmA titer was 1:200 (range, 1:5-1:2000) in the GFD and 1:100 (1:5-1:4000) in the gluten group. On intervention, the titers decreased significantly in favor of the GFD group ( Figure 1A) . The titers also subsequently decreased in all but 2 patients in the gluten group when they started a GFD. At baseline, TG2ab was positive in 88% of the EmA-positive participants. All 5 subjects who were negative for TG2ab had EmA titers of 1:5-1:50. Similar to EmA, there was a significant decrease in TG2ab in favor of GFD ( Figure 1B) . DGPab was positive in 80% of the subjects, with mean values of 69 AE 62 U in the GFD group and 70 AE 58 U in the gluten group, and changes after 1 year of -54 AE 59 U and 11 AE 38 U, respectively (P < .001).
Gastrointestinal Symptoms and Quality of Life
The baseline mean GSRS total score was 1.8 AE 0.6 in the GFD group and 1.7 AE 0.6 in the gluten group. After intervention, the total, indigestion, and reflux symptoms were reduced significantly in the GFD group (Figure 2A) . Subsequently, the total score (P ¼ .049) and indigestion (P ¼ .016) also decreased within the gluten group after starting a GFD. The PGWB total score was 112.2 AE 12.0 in the GFD group and 111.3 AE 11.0 in the gluten group at baseline, and anxiety was alleviated in the GFD group ( Figure 2B ). On intervention, the SF-36 social functioning was reduced in the gluten group ( Figure 2C ). Perception of current health as evaluated by the VAS improved in the GFD group ( Figure 1D ).
Laboratory Parameters
The mean laboratory values were within the reference range and no significant differences were observed in the changes between the groups during the intervention (Table 2) . Although there was no difference between the groups, within the GFD group the red blood cell folate (P < .001) and vitamin B12 values improved (P < .001); this also was seen later in the gluten group upon adaption of a GFD (P ¼ .005 and P ¼ .018, respectively).
Bone Mineral Density and Body Composition
In the GFD group the baseline mean T-score for the lumbar spine was -0.2 AE 1.5, and for the femur neck was -0.5 AE 1.2; the corresponding Z-scores were -0.1 AE 1.5 and -0.2 AE 1.0, respectively. In the gluten group the T-scores were -0.2 AE 1.7 and -0.3 AE 1.0, and the Z-scores were -0.3 AE 1.7 and -0.1 AE 1.0, respectively. Differences in BMD changes between the groups were not significant ( Table 3 ). The mean BMI was 27.0 AE 6.8 in the GFD group and 26.4 AE 3.7 in the gluten group; no subject was underweight but 55% were overweight or obese. There were no differences in BMI changes during the intervention (Table 3 ). The mean body fat percentage was 34.0 AE 8.9 in the GFD group and 28.9 AE 8.2 in the gluten group, and changes in body fat percentage did not significantly diverge between the groups (Table 3) .
Small-Bowel Mucosal Morphology and Inflammation
At the end of the study (after 2 years) the small-bowel mucosal biopsy results were opened. At baseline, the mean Vh/CrD was 1.0 AE 0.9 in the GFD group and 0.8 AE 0.8 There was a significant difference in the changes between the randomization groups after 1 year in EmA (P ¼ .003) and TG2ab (P ¼ .003), in the perception of health by VAS (P ¼ .017), and in the Vh/CrD (P < .001). On the VAS, the scale ranges from 0 to 100 mm and higher values indicate better subjective perception of current health. In Vh/CrD ratios, greater than 2.0 indicates normal small-bowel mucosal morphology. Figure 2 . Absolute differences between the study groups in changes in the (A) GSRS, (B) PGWB, and (C) SF-36 scores. The differences in changes between the intervention group (GFD) and the normal diet group (gluten) are shown after 1 year of study enrollment and are expressed as means and 95% confidence intervals. On the GSRS, higher scores denote more severe gastrointestinal symptoms, on the PGWB higher scores denote better self-perceived quality of life, and on the SF-36 higher scores denote better health status and quality of life. Values in each subdimension scores are calculated as a mean of the relevant items. EP, emotional problems; PP, physical problems.
in the gluten group. On intervention, a significant improvement in Vh/CrD was seen after 1 year on a GFD ( Figure 1D ), and the ratio also increased within the gluten group when they started the diet. At baseline, mucosal CD3þ IELs were greater than the reference value in 90% and dgþ IELs in all but one subject; differences in IEL changes between the groups were not significant ( Table 3) . The Vh/CrD was considered normal (>2.0) in 2 cases in both groups at baseline (Table 4) . Despite having morphologically normal small-bowel mucosal villi, these 4 subjects showed mucosal inflammation as measured by increased IELs; none of the study participants had completely normal mucosa at baseline. The 2 subjects with normal Vh/CrD in the GFD group evinced beneficial histologic, serologic, and clinical responses comparable with those with evident villous damage. Results in the gluten group were inconsistent because the other subject experienced unfavorable responses while the other beneficial responses while on gluten (Table 4 ). Table 4 also shows examples of the symptom-specific GSRS total, diarrhea, and pain scores in 2, by definition asymptomatic, subjects at baseline and after being on a GFD.
Other Clinical Evaluations
After 2 years, when the trial was completed, 92% of the subjects reported adherence to the GFD, and 8% reported dietary transgressions; 85% expected to remain on the diet in the future; 15% were not sure. Maintaining the GFD was considered "easy" by 5%, "goes by itself" by 67%, and "difficult" by 13%; 15% could not say. Finally, 58% experienced their celiac disease screening and diagnosis as positive or very positive, 42% were indifferent, and none were negative.
Discussion
The results of this randomized study showed that screen-detected and even apparently asymptomatic EmApositive patients benefit from a GFD as measured by extensive clinical, serologic, and histologic parameters. There was some previous evidence indicating improvement in the well being of screen-detected celiac disease patients on a GFD, [10] [11] [12] [13] [14] and we showed this now by a vigorous randomized approach. Here, the greatest differences between the groups on dietary intervention could be seen in serology and in mucosal morphology. For ethical reasons no NOTE. The values are expressed as means AE SD, except differences in the changes between the groups, which are expressed as means with the 95% confidence interval. a Calculated with the Student t test. subjects with evident symptoms were randomized and, in fact, the mean baseline quality of life was even better than previously observed in healthy controls. 10 Likewise, the mean laboratory parameters and BMD were within normal range; one cannot expect major improvements in individuals at such an early stage in celiac disease. Nonetheless, in favor of a GFD, there were also significant differences in the GSRS and quality-of-life scores. This randomized approach showed that subjects who thought they were asymptomatic experienced improvement in several objective disease scores upon adopting a GFD. These findings, as exemplified in Table 4 by a marked decrease in most of the GSRS scores on GFD, suggest that the patients may in fact have accepted mild symptoms as normal and recognized them as abnormal only later when on the diet. It is likely that the changes would have been more evident in the symptomatic subjects who were excluded here but commonly are found by active screening. 11, 14 In clinical settings many screen-detected patients also may suffer from atypical symptoms not being recognized as celiac disease. 13 Until now, active screening of celiac disease has been a subject of controversy. Because of the high prevalence and ambiguous clinical picture and existence of effective treatment, screening of at-risk groups or even the whole population has been suggested. 7, 8, 13, 25 Nevertheless, treatment benefit in apparently asymptomatic patients has remained unsolved. Notwithstanding the known positive effects of a GFD, it is expensive and socially isolating and may be detrimental to quality of life. Furthermore, availability of the products is limited and they may have lower nutritional value and palatability than their gluten-containing counterparts. Here, indeed, the SF-36 social functioning score decreased in the GFD group. Then again, besides objective serologic and histologic parameters, self-perceived GSRS scores and anxiety also improved and the majority of subjects showed excellent dietary adherence and were willing to continue on the diet, indicating that it was not considered harmful. There also has been concern that obese celiac patients might gain more weight on a GFD 26 ; however, the present and other recent results do not support this concept. 27, 28 Furthermore, although not as apparent here, there is evidence that screen-detected patients may have a decreased quality of life and BMD that improves on a GFD. [10] [11] [12] [13] Nevertheless, besides the decrease in social functioning seen here, in some screen-detected patients the celiac disease diagnosis may lead to increased anxiety and health concerns. 10 Given that unrecognized celiac disease may not necessarily increase the risk of malignancy or mortality, [29] [30] [31] the consequences of possible screening must be weighed carefully in advance on an individual basis. Furthermore, because the present study was conducted in individuals belonging to an at-risk group, the question of population-based mass screening remains a subject for future studies.
As a result of increasing celiac disease screening, a substantial number of seropositive individuals manifest with only mild enteropathy (ie, Marsh grades I-II). 15 Thus far, strict criteria with the demonstration of villous atrophy (Marsh III) have been necessary to ensure a reliable diagnosis of this lifelong and restrictive disorder. However, the modern biomarkers, particularly EmA, have shown almost 100% specificity for celiac disease.
1 Furthermore, we previously showed that most false-positive cases with initially morphologically normal villi (Marsh I-II) eventually will develop mucosal atrophy if they continue on gluten. 32 Moreover, a randomized trial showed that these EmA-positive subjects already benefit from a GFD before villous atrophy (the end stage of the histologic damage) develops. 15 Accordingly, the latest diagnostic criteria of celiac disease have begun to accept milder forms of enteropathy as diagnostic in seropositive patients. 17 These findings suggest that the hitherto used grouped classifications are no longer optimal in the diagnosis of celiac disease. Nevertheless, because serology and symptoms have been shown to be unreliable markers for the mucosal improvement and dietary adherence in celiac disease, 6 we considered it necessary to use histology as the primary outcome in this study; this is likely even more important in screen-detected subjects with mild clinical presentation. To detect even minor changes in morphology, validated and quantitative Vh/CrD was used in this study instead of grouped classification. 33 In this study, all EmA-positive subjects had celiac disease-associated HLA and all but 1 subject had an increased dgþ IEL count, which is further proof of the presence of celiac disease irrespective of the degree of villous damage. 22, 34, 35 Furthermore, the seropositive cases with clear mucosal inflammation but normal villous morphology showed a beneficial response to GFD in most of the measured parameters. Nevertheless, it still remains unclear if all EmA-positive, screen-detected individuals should be treated. None of the participants in this study or in our previous randomized study investigating the role of EmA in diagnostics 15 had a completely normal biopsy (Marsh 0) at baseline and further prospective studies are needed to decipher whether these subjects truly benefit from a GFD. If so, even the universal need for a biopsy in EmA-positive adults might be questioned. Such studies, however, may be difficult to execute because a very large at-risk cohort likely should be screened to achieve sufficient power.
There were certain limitations to the present study. It was impossible to blind subjects to a GFD and some placebo effect may have accounted for the results. Furthermore, subjects in the gluten group might have been more sensitive to possible celiac disease-associated symptoms, and we cannot exclude gluten reduction at the individual level. Because EmA positivity was an inclusion criterion, there were no EmA-negative TG2ab-positive, or entirely seronegative, patients, and the results from this study should not be extended to apply to such individuals. Another limitation was that no other indicators for bone metabolism apart from BMD, for example, vitamin D levels, were measured. It also must be borne in mind that, in general, there is good knowledge of celiac disease and easy availability of glutenfree products in Finland, but this might not be the case in many other countries, for example, in the United States. 9, 36 In contrast to celiac disease in general, 1 in this study 65% of the randomized subjects were males, the reason being that a considerably higher proportion of females than males fulfilled the age exclusion criteria.
In conclusion, our randomized study showed that apparently asymptomatic EmA-positive subjects benefit from serologic screening and a subsequent GFD. The results support active screening of celiac disease in at-risk groups. However, because of the possible detrimental effects of a GFD in social functioning, the consequences of screening must be prejudged on an individual basis. Furthermore, prospective studies are needed to unravel whether screendetected seropositive subjects with completely normal small-bowel mucosal histology should be treated.
